Glaxosmithkline | GSK - Operating Expenses


Glaxosmithkline reported GBP5.34B in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
Aurora Cannabis CAD 48.04M 81.94M Mar/2026
Bausch Health Companies USD 2.04B 42M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Canopy Growth CAD 98.72M 11.51M Mar/2026
Corcept Therapeutics USD 214.5M 16.87M Mar/2026
Drreddys Laboratories INR 74.33B 1.4B Mar/2026
Eli Lilly USD 10.02B 285M Mar/2026
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Glaxosmithkline GBP 5.34B 3.83B Mar/2026
J&J USD 17.83B 388M Jun/2026
Merck USD 18.17B 8.01B Mar/2026
Novartis USD 9.29B 507M Mar/2026
Pacira USD 172.75M 20.93M Mar/2026
Perrigo USD 935.6M 89.6M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
Phibro Animal Health USD 361.83M 29.47M Mar/2026
Prestige Brands USD 206.12M 5.17M Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 9.31B 1.2B Mar/2026
Supernus Pharmaceuticals USD 1.08B 879.06M Mar/2026
Takeda JPY 1.11T 85.29B Mar/2026
Teva Pharmaceutical Industries USD 3.22B 1000M Mar/2026
Zoetis USD 3.23B 1.68B Mar/2026